EGFR inhibitor ERAS-801

{
  "id": "MLC-T-ONC-013245",
  "term": "EGFR inhibitor ERAS-801",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable, central nervous system (CNS) penetrating inhibitor of epidermal growth factor receptor (EGFR; ErbB1; HER1) amplifications driven by both oncogenic EGFR variants and wildtype EGFR, with potential antineoplastic activity. Upon oral administration, EGFR inhibitor ERAS-801 selectively targets, binds to and inhibits the activity of EGFR. This prevents EGFR-mediated signaling. This may induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated and overexpressed in many tumors, plays a key role in tumor cell proliferation and tumor vascularization. ERAS-801 is able to penetrate the blood-brain-barrier (BBB) and may therefore exert its activity against EGFR-driven CNS primary tumors and CNS metastases.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/egfr-inhibitor-eras-801/"
}